top of page
FORME_Plan de travail 1.png

Newsroom

Sep 20, 2024

La biotech lyonnaise PK MED, qui fabrique des implants microscopiques permettant
de libérer des molécules de manière contrôlée et localisée, vient de recevoir
1,5 M€ d'aides de Bpifrance pour accélérer dans un programme d'amélioration
des greffes de moelle.

Jul 29, 2024

PK MED appoints Yvonne Bokelman as Chairman of the Board of Directors.

Jul 24, 2024

PK MED receives €1.5M DeepTech non-dilutive financing from Bpifrance for the development of a local cell-homing implant to enhance bone marrow transplantation.

Feb 26, 2024

PK MED announces FDA clearance to initiate its clinical program for PKM-01, targeting local treatment of gout flares, directly commencing with a Phase 2 trial.

Feb 4, 2024

PK MED is proud to receive support from the Auvergne-Rhône-Alpes Region as part of the development of its activities. As France’s 2nd leading region for research and the 5th in Europe, it offers a dynamic innovation ecosystem with over 600 laboratories and 40,000 researchers.

© PK MED – 2024

Legal notice

bottom of page